Bayer stock gains 1.46 percent as Q2 growth holds

Published on 10/06/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock was trading at EUR 44.60 on October 6, 2026, while Q2 sales reached EUR 10.872 billion. The consensus covers 18 analysts with an average target of EUR 58.22.

Architektur-Render eines modernen gläsernen Forschungscampus mit Grünflächen — Bayer AG (DE000BAY0017): modernes Architektur-Render eines gläsernen Pharma-Forschungscampus mit Grünflächen bei strahlendem Tageslicht, Illustration mit AI erstellt.

Bayer stock (ISIN DE000BAY0017) was trading at EUR 44.60 on Xetra on October 6, 2026, at 3:44 p.m. CEST, up 1.46 percent from the prior close. The move puts the shares below the 52-week high of EUR 53.92, while Bayer's latest operating figures provide the more durable reference point for the company.

Q2 sales rose 2.2 percent

According to Bayer in its Q2 2026 report, group sales adjusted for currency and portfolio effects increased 2.2 percent to EUR 10.872 billion. EBITDA before special items rose 1.9 percent to EUR 2.144 billion, while core earnings per share increased 16.7 percent.

The figures show a mixed but measurable operating improvement: sales growth remained moderate, while the earnings increase was stronger than the top-line advance. That distinction matters because Bayer is balancing Pharmaceuticals and Crop Science against litigation and financing pressures.

Ohio investment adds a growth signal

Bayer said on October 2, 2026, that it plans to invest USD 2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio. The project is expected to create 600 new high-value jobs, according to Bayer.

The investment gives the current share move a concrete strategic backdrop: Bayer is expanding production capacity in the United States while its latest results show positive momentum in adjusted earnings. The size of the project also makes capital allocation a central issue alongside operational growth.

Analysts see higher value

The consensus published by MarketScreener is Outperform from 18 analysts, with an average target of EUR 58.22. The same overview lists a last close of EUR 49.31 and an average-target spread of 18.07 percent.

J.P. Morgan maintained a Buy rating and a EUR 61.00 target in a report dated October 1, 2026, according to Markets Insider. The analyst view is constructive, but the upcoming quarterly report will test whether earnings growth can continue across Bayer's divisions.

Bayer stock trades below its yearly high

Bayer stock was trading at EUR 44.60 on Xetra on October 6, 2026, at 3:44 p.m. CEST. The quote was above the session low of EUR 44.17 and below the session high of EUR 45.26, with a market capitalization of EUR 43.8 billion and volume of 825,153 shares.